The effect of Kuntai capsule on ovarian function in cisplatin-induced premature ovarian insufficiency rats.

Front Endocrinol (Lausanne)

Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.

Published: February 2023

AI Article Synopsis

  • This study evaluated the effect of Kuntai capsule on ovarian function in rats with cisplatin-induced premature ovarian insufficiency (POI).
  • Seventy-four female Sprague-Dawley rats were used, with some receiving Kuntai capsules and others getting control treatments or Estradiol for 28 days.
  • Results showed that rats treated with low and high doses of Kuntai capsule had improved hormone levels and ovarian health compared to the model Control group, suggesting Kuntai capsule may have beneficial effects on ovarian function.

Article Abstract

Objective: This study aims to evaluate the effect of Kuntai capsule on ovarian function in cisplatin-induced premature ovarian insufficiency rats and to explore the mechanism of Kuntai capsule on the ovarian function of rats.

Methods: Seventy-four female Sprague-Dawley rats were used for this study. Eight of the rats were randomly assigned to the Control group. The remaining sixty-six rats were utilized to establish the POI model Cisplatin and then randomly divided into four groups: the model Control group, the Estradiol group, and groups treated with low and high doses of Kuntai capsule. For the 28-day administration, the Control and model Control groups were intragastrically administered with 2.0 mL of 0.9% sodium chloride daily, the Estradiol group with 2.0 mL of Estradiol suspension (0.2mg/kg/d), and the low dose Kuntai capsule group and the high dose Kuntai capsule group with 2.0 mL of Kuntai capsule suspension (0.6g/kg/d, 1.8g/kg/d, respectively). Sex hormone levels, estrous cycle, and ovarian coefficient of the five groups were compared, histological sections analyzed follicle counts, and the protein expressions of growth differentiation factor 9, light chain 3 A-II, and Beclin 1 in the ovarian tissue were detected by Western blotting.

Results: After the 28-day administration, the serum Estradiol and Follicle-Stimulating Hormone levels of the group treated with low dose of Kuntai capsule were not significantly different from the Control group, the serum anti-Müllerian Hormone level of the group treated with high dose of Kuntai capsule was significantly higher than the Estradiol group. The estrous cycle of the group treated with low dose of Kuntai capsule was significantly lower than the model Control group. Regarding ovarian coefficient, resting and growing follicles, growth differentiation factor 9, light chain 3 A-II, and Beclin 1 expression, both Kuntai capsule groups outperformed the model Control group with the statistical difference (<0.05).

Conclusion: Kuntai capsule can improve the estrous cycle and ovarian coefficient of rats with premature ovarian insufficiency, maintain the number of resting and growing follicles, and up-regulate the protein expression of growth differentiation factor 9, light chain 3 A-II, and Beclin 1 of rats' ovaries.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892898PMC
http://dx.doi.org/10.3389/fendo.2022.1097165DOI Listing

Publication Analysis

Top Keywords

kuntai capsule
44
control group
20
dose kuntai
20
model control
16
group
13
capsule ovarian
12
ovarian function
12
estradiol group
12
treated low
12
low dose
12

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!